NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

全球Erlotinib市場:2013年∼2023年的預測

Global Erlotinib Market, 2013-2023

出版商 Market Krystal 商品編碼 927434
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
全球Erlotinib市場:2013年∼2023年的預測 Global Erlotinib Market, 2013-2023
出版日期: 2019年11月01日內容資訊: 英文
簡介

全球範圍內癌症疾病數量的增加對抗癌藥物的需求增加以及製藥業的快速發展,推動了全球Erlotinib市場的成長

本報告提供全球Erlotinib市場的相關調查,提供產品概要,各銷售額·各交易量的市場規模,各類型·用途·企業·各地區的市場分析,競爭情形,主要企業的簡介等資訊。

第1章 簡介

  • 報告的目的
  • 調查手法
  • 摘要整理

第2章 產品概要

  • 產品分析
  • 主要企業的組合分析
  • 價值鏈分析
  • 市場動態

第3章 全球市場分析

  • 市場規模(2013-2023)
    • 各銷售額
    • 各交易量
  • 市場佔有率(2013-2023)
    • 各類型
    • 各用途
    • 各企業
    • 各地區

第4章 北美

第5章 歐洲

第6章 亞太地區

第7章 中東

第8章 非洲

第9章 南美

第10章 競爭情形

  • Tarceva
    • 企業概要
    • 產品系列
    • 最近的開發
    • 財務分析
  • 其他的企業

第11章 附錄

目錄

Erlotinib is a tyrosine kinase receptor inhibitor and classified as epidermal growth factor receptor (EGFR) inhibitor - protein-tyrosine kinase inhibitor. This is used as anticancer drug. Erlotinib is used in the therapy of advanced or metastatic pancreatic cancer, non-small cell lung cancer and any other types of cancer.

Erlotinib act as antineoplastic agents. Erlotinib therapy is associated with transient elevations in serum aminotransferase levels during therapy and rare instances of clinically apparent acute liver injury. Erlotinib added to chemotherapy improved overall survival of the patients.Erlotinib is about 60% absorbed after oral administration and its bioavailability is substantially increased by food to almost 100%. Peak plasma levels occur 4 hours after dosing. The solubility of erlotinib is pH dependent. Erlotinib solubility decreases as pH increases. Symptoms of overdose include diarrhea, rash, and liver transaminase elevation.

The global erlotinib market research report sheds light on the market circumstances by carrying out primary and secondary research for more than 320 hours. As per the report, the global erlotinib market is growing at a fast pace and increasing its geographical footprint rapidly. The global erlotinib market is valued at US $ xxx million dollars in 2018 which is forecast to grow at CAGR of xx% and reach a massive US $ xxx million dollars by the end of 2023 in value.

The major growth driver for Erlotinib market globally is the rapid expansion in the pharmaceutical industry. With the growing cancer disease around the world, the demand of anticancer drug increases.

Erlotinib enjoy wide usage across all major regions in the world including Europe, APAC, North America, Middle East and Africa, and Latin America. These regions serve large number of manufacturers and are hence responsible for the growth of erlotinib market globally.The companies that lead erlotinib market are Tarceva (US), Astellas Pharma & Genentech (US), Chugai & Roche (japan).

Research Methodology

The research procedure begins with the bifurcation of various market segments of global erlotinib market, followed by detection of factors affecting the growth each segment. Then, the market forecasts were built based on the inputs given by the business leaders across erlotinib industry value chain. Market Krystal held more than 40 interviews for this study, details of which are mentioned:

By company type: Manufacturers (35%), Suppliers (25%), Consumers (20%), Researchers (10%), Independent industry consultant (10%)

By geography: North America (25%), Asia (40%), Europe (20%), Rest of the World (15%)

By designation: Top level (40%), Operation level (20%), Mid-level (40%)

Contents of the report:

  • Insights on the global erlotinib industry dynamics
  • Estimation of the present global erlotinib market size in terms of value and volume
  • Global erlotinib market breakup based on type and application
  • Substantiated global erlotinib market forecast for the next five years.
  • In depth analysis of the leading companies working across different nodes of global erlotinib industry value chain

1. Introduction

  • Purpose of the report
  • Research methodology
  • Executive summary

2. Product Overview

  • Product analysis
  • Portfolio analysis of top companies
  • Value chain analysis
  • Market dynamics

3. Global Market Analysis

  • Global erlotinib market size (2013-2023)
    • By value
    • By volume
  • Global erlotinib market share (2013-2023)
    • By type
    • By application
    • By company
    • By geography

4. North America Market Analysis

  • North America erlotinib market size (2013-2023)
    • By value
    • By volume
  • North America erlotinib market share (2013-2023)
    • By type
    • By application
    • By company
    • By geography

5. Europe Market Analysis

  • Europe erlotinib market size (2013-2023)
    • By value
    • By volume
  • Europe erlotinib market share (2013-2023)
    • By type
    • By application
    • By company
    • By geography

6. Asia Pacific Market Analysis

  • Asia Pacific erlotinib market size (2013-2023)
    • By value
    • By volume
  • Asia Pacific erlotinib market share (2013-2023)
    • By type
    • By application
    • By company
    • By geography

7. Middle East Market Analysis

  • Middle East erlotinib market size (2013-2023)
    • By Value
    • By volume
  • Middle East erlotinib market share (2013-2023)
    • By type
    • By application
    • By company
    • By geography

8. Africa Market Analysis

  • Africa erlotinib market size (2013-2023)
    • By value
    • By volume
  • Africa erlotinib market share (2013-2023)
    • By type
    • By application
    • By company
    • By geography

9. Latin America Market Analysis

  • Latin America erlotinib market size (2013-2023)
    • By value
    • By volume
  • Latin America erlotinib market share (2013-2023)
    • By type
    • By application
    • By company
    • By geography

10. Competitive Intelligence

  • Tarceva
    • Company overview
    • Product portfolio
    • Recent developments
    • Financial analysis
  • Company 2
    • Company overview
    • Product portfolio
    • Recent developments
    • Financial analysis
  • Company 3
    • Company overview
    • Product portfolio
    • Recent developments
    • Financial analysis
  • Company 4
    • Company overview
    • Product portfolio
    • Recent developments
    • Financial analysis
  • Company 5
    • Company overview
    • Product portfolio
    • Recent developments
    • Financial analysis
  • Company 6
    • Company overview
    • Product portfolio
    • Recent developments
    • Financial analysis
  • Company 7
    • Company overview
    • Product portfolio
    • Recent developments
    • Financial analysis
  • Company 8
    • Company overview
    • Product portfolio
    • Recent developments
    • Financial analysis
  • Company 9
    • Company overview
    • Product portfolio
    • Recent developments
    • Financial analysis

11. Appendix

  • Primary research breakup
  • List of interview participants
  • Discussion guide
  • Interview transcript
  • About Market Krystal Team